Logo image of VERA

VERA THERAPEUTICS INC (VERA) Stock Fundamental Analysis

NASDAQ:VERA - Nasdaq - US92337R1014 - Common Stock - Currency: USD

23.31  +0.73 (+3.23%)

After market: 23.56 +0.25 (+1.07%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to VERA. VERA was compared to 558 industry peers in the Biotechnology industry. VERA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. VERA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year VERA has reported negative net income.
In the past year VERA has reported a negative cash flow from operations.
In the past 5 years VERA always reported negative net income.
In the past 5 years VERA always reported negative operating cash flow.
VERA Yearly Net Income VS EBIT VS OCF VS FCFVERA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

The Return On Assets of VERA (-28.76%) is better than 68.10% of its industry peers.
The Return On Equity of VERA (-32.80%) is better than 75.81% of its industry peers.
Industry RankSector Rank
ROA -28.76%
ROE -32.8%
ROIC N/A
ROA(3y)-48.55%
ROA(5y)-56.49%
ROE(3y)-78.86%
ROE(5y)-77.96%
ROIC(3y)N/A
ROIC(5y)N/A
VERA Yearly ROA, ROE, ROICVERA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VERA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VERA Yearly Profit, Operating, Gross MarginsVERA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for VERA has been increased compared to 1 year ago.
The number of shares outstanding for VERA has been increased compared to 5 years ago.
Compared to 1 year ago, VERA has an improved debt to assets ratio.
VERA Yearly Shares OutstandingVERA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
VERA Yearly Total Debt VS Total AssetsVERA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

VERA has an Altman-Z score of 10.79. This indicates that VERA is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 10.79, VERA belongs to the best of the industry, outperforming 87.63% of the companies in the same industry.
VERA has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.10, VERA is doing worse than 65.23% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z 10.79
ROIC/WACCN/A
WACCN/A
VERA Yearly LT Debt VS Equity VS FCFVERA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 27.68 indicates that VERA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 27.68, VERA belongs to the top of the industry, outperforming 96.59% of the companies in the same industry.
A Quick Ratio of 27.68 indicates that VERA has no problem at all paying its short term obligations.
The Quick ratio of VERA (27.68) is better than 96.59% of its industry peers.
Industry RankSector Rank
Current Ratio 27.68
Quick Ratio 27.68
VERA Yearly Current Assets VS Current LiabilitesVERA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

VERA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -44.93%.
EPS 1Y (TTM)-44.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-44.64%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 33.55% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-21.46%
EPS Next 2Y-12.18%
EPS Next 3Y2.72%
EPS Next 5Y33.55%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VERA Yearly Revenue VS EstimatesVERA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
VERA Yearly EPS VS EstimatesVERA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VERA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VERA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VERA Price Earnings VS Forward Price EarningsVERA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VERA Per share dataVERA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.18%
EPS Next 3Y2.72%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VERA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VERA THERAPEUTICS INC

NASDAQ:VERA (6/25/2025, 8:17:18 PM)

After market: 23.56 +0.25 (+1.07%)

23.31

+0.73 (+3.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners108.03%
Inst Owner Change0.2%
Ins Owners1.05%
Ins Owner Change2.48%
Market Cap1.49B
Analysts84
Price Target66.81 (186.62%)
Short Float %14.93%
Short Ratio4.8
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.81%
Min EPS beat(2)-8.04%
Max EPS beat(2)15.67%
EPS beat(4)1
Avg EPS beat(4)-6.9%
Min EPS beat(4)-26.69%
Max EPS beat(4)15.67%
EPS beat(8)3
Avg EPS beat(8)0.65%
EPS beat(12)4
Avg EPS beat(12)-4.28%
EPS beat(16)6
Avg EPS beat(16)-4.01%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.65%
PT rev (3m)0.06%
EPS NQ rev (1m)1.75%
EPS NQ rev (3m)-4.01%
EPS NY rev (1m)-0.06%
EPS NY rev (3m)-3.54%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.78
P/tB 2.78
EV/EBITDA N/A
EPS(TTM)-3
EYN/A
EPS(NY)-3.46
Fwd EYN/A
FCF(TTM)-2.45
FCFYN/A
OCF(TTM)-2.43
OCFYN/A
SpS0
BVpS8.39
TBVpS8.39
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.76%
ROE -32.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.55%
ROA(5y)-56.49%
ROE(3y)-78.86%
ROE(5y)-77.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 27.68
Quick Ratio 27.68
Altman-Z 10.79
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-44.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-44.64%
EPS Next Y-21.46%
EPS Next 2Y-12.18%
EPS Next 3Y2.72%
EPS Next 5Y33.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-89.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-31.99%
EBIT Next 3Y12.29%
EBIT Next 5YN/A
FCF growth 1Y-84.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-82.85%
OCF growth 3YN/A
OCF growth 5YN/A